PETX Aratana Therapeutics, Inc.

Item 9.01 Financial Statements and Exhibits .



(d) Exhibits:





Forward-Looking Statements



Some of the information contained in this report, including information with respect to the Company’s plans and strategy for its business, includes forward-looking statements that involve risks and uncertainties. In this report, the words “anticipates,” “believes,” “expects,” “intends,” “future,” “could,” “estimates,” “plans,” “would,” “should,” “potential,” “continues” and similar words or expressions (as well as other words or expressions referencing future events, conditions or circumstances) identify forward-looking statements. These forward-looking statements include without limitation statements regarding the anticipated commercial availability of NOCITA to veterinarians in the fall of 2016. Such statements involve risks, uncertainties and other important factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements  expressed or implied by the forward-looking statements, including but not limited to: the Company’s history of operating losses and its expectation that the Company will continue to incur losses for the foreseeable future; failure to obtain sufficient capital to fund the Company’s operations; risks relating to the impairment of intangible assets AT-004, AT-005, AT-007 and AT-011; unstable market and economic conditions; restrictions on the Company’s financial flexibility due to the terms of its credit facility; the Company’s substantial dependence upon the success of its product candidates; development of the Company’s biologic product candidates is dependent upon relatively novel technologies and uncertain regulatory pathways, and biologics may not be commercially viable; denial or delay of regulatory approval for the Company’s existing or future product candidates; failure of the Company’s product candidates that receive regulatory approval to obtain market approval or achieve commercial success; failure to realize anticipated benefits of the Company’s acquisitions and difficulties associated with integrating the acquired businesses; development of pet therapeutics is a lengthy and expensive process with an uncertain outcome; competition in the pet therapeutics market, including from generic alternatives to the Company’s product candidates, and failure to compete effectively; failure to identify, license or acquire, develop and commercialize additional product candidates; failure to attract and retain senior management and key scientific personnel; the Company’s reliance on third-party manufacturers, suppliers and partners; regulatory restrictions on the marketing of the Company’s product candidates; the Company’s small commercial sales organization, and any failure to create a sales force or collaborate with third-parties to commercialize the Company’s product candidates; difficulties in managing the growth of the company; significant costs of being a public company; risks related to the restatement of the Company’s financial statements for the year ended December 31, 2013, and the identification of a material weakness in its internal control over financial reporting; changes in distribution channels for pet therapeutics; consolidation of the Company’s veterinarian customers; limitations on the Company’s ability to use its net operating loss carryforwards; impacts of generic products; safety or efficacy concerns with respect to the Company’s product candidates; effects of system failures or security breaches; failure to obtain ownership of issued patents covering the Company’s product candidates or failure to prosecute or enforce licensed patents; failure to comply with the Company’s obligations under its license agreements; effects of patent or other intellectual property lawsuits; failure to protect the Company’s intellectual property; changing patent laws and regulations; non-compliance with any legal or regulatory requirements; litigation resulting from the misuse of the Company’s confidential information; the uncertainty of the regulatory approval process and the costs associated with government regulation of the Company’s product candidates; failure to obtain regulatory approvals in foreign jurisdictions; effects of legislative or regulatory reform with respect to pet therapeutics; the volatility of the price of the Company’s common stock; the Company’s status as an emerging growth company, which could make the Company’s common stock less attractive to investors; dilution of the Company’s common stock as a result of future financings; the influence of certain significant stockholders over the Company’s business; and provisions in the Company’s charter documents and under Delaware law could delay or prevent a change in control. These and other important factors discussed under the caption "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on March 15, 2016, along with the Company’s other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this report.  Any such forward-looking statements represent management's estimates as of the date of this report. While the Company may elect to update such forward-looking statements at some point in the future, the Company disclaims any obligation to do so, even if subsequent events cause the Company’s views to change. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this report.